Pharmacokinetic‐pharmacodynamic profile of systemic nitric oxide‐synthase inhibition with L‐NMMA in humans

15 healthy subjects (n=7 in study 1, n=8 in study 2)

Study 1: L-NMMA 3 mg/kg i.v. over 5 min. Study 2: L-arginine 17 mg/kg/min i.v. over 30 min coinfused with a primed constant infusion of 50 microg/kg/min L-NMMA.

Plasma pharmacokinetics, systemic haemodynamics, cardiac output (CO), fundus pulsation amplitude (FPA), and NO-exhalation (exhNO)surrogate